Preclinical stage biotechnology company Microviable Therapeutics SL has raised €1.5 million seed funding from private medical group, Inmunomet Intolerancia y Disbiosis SL.
Microviable will use the funding to enhance its therapeutic development platform and advance the pipeline to the clinical stage.
The company’s lead product, MVT-201, is a biological drug based on complete microbiota (HiPMTM) for undisclosed targets.
The investment will enable Microviable to focus on its therapeutics while increasing its facilities and expanding the team.
Claudio Hidalgo Cantabrana, PhD, co-founder and CEO at Microviable, said:
“We are really excited for Microviable´s future and grateful for this opportunity to bring novel solutions to healthcare with the ultimate goal of improving the patients’ quality of life.
“We wanted a strategic partner that shares our vision of using microbiota-derived biological drugs to treat patients while providing smart capital, and Inmunomet fulfills all of our expectations.”
Inmunomet is a private medical group specialising in intolerances and gut dysbiosis related disorders.
With this investment, the group is ‘seeking to be part of Microviable´s growth being ahead on the development of novel solutions based on microbiota-derived biotherapeutic products.’
Microviable Therapeutics SL, spun out from the Spanish National Research Council in 2016, focuses on developing novel technologies and therapeutic products from the microbiota.
In March, the company announced that it had entered into a contractual agreement with BCD Bioscience to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome.
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- News3 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- AI6 days ago
AI model predicts breast cancer risk without racial bias
- Medtech4 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI2 weeks ago
Humans make better cancer treatment decisions than AI, study finds